Evaluating the impact of a Risk Evaluation and Mitigation Strategy with tolvaptan to monitor liver safety in patients with autosomal dominant polycystic kidney disease.

Autor: Estilo, Alvin1 (AUTHOR) alvin.estilo@otsuka-us.com, Tracy, LaRee1 (AUTHOR), Matthews, Carol2 (AUTHOR), Riggen, Michele2 (AUTHOR), Stemhagen, Annette2 (AUTHOR), Wilt, Timothy1 (AUTHOR), Krakovich, Anatoliy1 (AUTHOR), Jones-Burton, Charlotte1 (AUTHOR), George, Vinu1 (AUTHOR), McQuade, Robert1 (AUTHOR), Rahman, Mirza1 (AUTHOR)
Zdroj: Clinical Kidney Journal. Aug2022, Vol. 15 Issue 8, p1553-1561. 9p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje